| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised … MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ... The Lancet 395 (10231), 1208-1216, 2020 | 1447 | 2020 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 979 | 2018 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 661 | 2021 |
| Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 367 | 2019 |
| Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 252 | 2020 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 234 | 2019 |
| Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu … SP Thang, J Violet, S Sandhu, A Iravani, T Akhurst, G Kong, AR Kumar, ... European urology oncology 2 (6), 670-676, 2019 | 159 | 2019 |
| TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer … MS Hofman, L Emmett, J Violet, A Y. Zhang, NJ Lawrence, M Stockler, ... BJU international 124, 5-13, 2019 | 137 | 2019 |
| Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617 J Ferdinandus, J Violet, S Sandhu, RJ Hicks, AS Ravi Kumar, A Iravani, ... European journal of nuclear medicine and molecular imaging 47, 2322-2327, 2020 | 123 | 2020 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 113 | 2022 |
| Thyroid autoimmunity and recurrent spontaneous abortion in Iran: a case-control study AT Iravani, MM Saeedi, J Pakravesh, S Hamidi, M Abbasi Endocrine Practice 14 (4), 458-464, 2008 | 106 | 2008 |
| Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol A Iravani, B Solomon, DA Pattison, P Jackson, A Ravi Kumar, G Kong, ... Thyroid 29 (11), 1634-1645, 2019 | 94 | 2019 |
| TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Lancet 397 (10276), 797-804, 2021 | 85 | 2021 |
| TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC … MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020 | 79 | 2020 |
| Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution G Ferreira, A Iravani, MS Hofman, RJ Hicks Cancer Imaging 19, 1-10, 2019 | 78 | 2019 |
| Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, MS Hofman, L Emmett, J Calais, ... European journal of nuclear medicine and molecular imaging 50 (9), 2830-2845, 2023 | 73 | 2023 |
| Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies A Iravani, J Violet, A Azad, MS Hofman Prostate cancer and prostatic diseases 23 (1), 38-52, 2020 | 68 | 2020 |
| Cold kit for prostate-specific membrane antigen (PSMA) PET imaging: phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer MS Hofman, P Eu, P Jackson, E Hong, D Binns, A Iravani, D Murphy, ... Journal of Nuclear Medicine 59 (4), 625-631, 2018 | 65 | 2018 |
| Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in … E Lopci, RJ Hicks, A Dimitrakopoulou-Strauss, L Dercle, A Iravani, ... European journal of nuclear medicine and molecular imaging 49 (7), 2323-2341, 2022 | 63 | 2022 |
| TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 40 (16_suppl), 5000-5000, 2022 | 58 | 2022 |
Professor Michael S. HofmanClinician-Scientist, Peter MacCallum Cancer Centre & University of Melbourne在 petermac.org 的电子邮件经过验证
